FoundationOne ® CDx gene profiling in Japanese pancreatic ductal adenocarcinoma patients: a single-institution experience
ConclusionsCurrently, FoundationOne ® CDx might be difficult to use on PDAC patients, although further investigations with larger study populations are called for.
Source: Surgery Today - Category: Surgery Source Type: research
More News: Adenocarcinoma | Chemotherapy | Genetics | Japan Health | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Pancreas | Pancreatic Cancer | Study | Surgery